Navigation Links
Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
Date:5/27/2009

body that binds to the cellular membrane component phosphatidylserine (PS) that is usually located inside cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. By binding to PS, bavituximab is believed to help mobilize the body's immune system to destroy the tumor and the tumor blood vessels. Bavituximab currently is in two separate Phase II trials in combination with paclitaxel and carboplatin for the treatment of advanced breast cancer and non-small cell lung cancer, and in a third Phase II trial in combination with docetaxel in advanced breast cancer patients. A Phase I bavituximab monotherapy trial in advanced solid cancers is also continuing.

About Phosphatidylserine (PS)

The rapid and disorganized growth that is the hallmark of cancer results in the exposure of the lipid phosphatidylserine (PS) on the surface of tumor blood vessels. Since these phospholipids are typically not exposed on the surface of normal tissues, they represent a unique target for anti-cancer treatments. Bavituximab binds specifically to these phospholipids exposed on the surface of the cells lining tumor blood vessels. Once bound, bavituximab alerts the body's immune system to attack the blood vessels, inhibiting tumor growth and proliferation. In addition, a growing body of evidence supports the active role of PS in immune signaling, with recent research showing that exposed PS can have an immunosuppressive effect and dampen the body's normal immune response to cancer. By binding to and blocking PS, bavituximab is believed to boost the body's ability to combat cancer via this second mechanism. Further information on the role of exposed PS in the tumor environment can be found in the Anti-PS Technical Backgrounder posted on Peregrine's homepage at www.peregrineinc.com.

<
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Senesco Presents Pre-Clinical Multiple Myeloma Data at the 12th Annual Meeting of the American Society of Gene Therapy
2. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
3. Medarex to Host Clinical Program Update Conference Call on Tuesday, June 2, 2009
4. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
5. Spectros T-Stat Tissue Oximeter Clinical Studies Presented at PAS (Pediatric Academic Societies) Conference
6. SemBioSys plant-derived Apo AI(Milano) demonstrates encouraging biologic activity in seven preclinical models
7. goBalto Partners with Maya Clinicals to Expand Its List of Investigator Sites
8. Oncothyreons PX-866 is effective in preclinical model of pulmonary fibrosis
9. Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology
10. Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
11. Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... August 22, 2014 Today the Academy of ... United States Court of Appeals for the D.C. Circuit challenging ... published in the Federal Register on June 25, 2014. ... contrary to the text and intent of the FAA Modernization ... Congress’ specific prohibition on any new rules or regulations regarding ...
(Date:8/22/2014)... 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... 30, 2014.  Biorem,s complete 2014 second quarter financial statements and MD&A have ... June 30, , Six-months ended June 30, ( ... 2013 , 2014 , 2013 Revenue , ... 9,195 Gross profit , 56 , 1,485 ...
(Date:8/22/2014)... University of Surrey have discovered how the receptors responsible ... genes. , The new study, published today in ... activity in turn regulates the cycle of all cells ... that the local biological clock and its control are ... clock in bladder physiology and ageing. , ...
(Date:8/22/2014)... a study published today (August 22nd), in the ... the Champalimaud Neuroscience Programme establish the effect of ... of advanced genetic and optical techniques., "Serotonin is ... a wide range of brain functions, from the ... of complex emotional behaviours, This neurotransmitter is also ...
Breaking Biology Technology:AMA Files Petition for Review of FAA’s Interpretive Rule 2Biorem Reports 2014 Second Quarter Results 2Biorem Reports 2014 Second Quarter Results 3Treatment for overactive bladder and irritable bowel syndrome advanced through pioneering research 2From happiness to pain: Understanding serotonin's function 2
... Wis. -- Gov. Jim Doyle says taxpayers will ... total of nearly $80 million over the lifetime of ... and services, including a number of technology areas. , ... Accountability, Consolidation, and Efficiency (ACE) Initiative to ensure ...
... of Milwaukee is one of six first-year college students from ... Online's "Project Freshman," a new documentary series that will be ... Friday, Sept. 23. New episodes will air every Thursday. The ... were given digital video cameras and were trained in their ...
... -- The Wisconsin Technology Council has teamed with PropertyDrive, ... database of commercial real estate on the Tech Council ... on the site's Resource Center, Commercial Property Search. , ... locate or expand in Wisconsin the ability to search ...
Cached Biology Technology:
(Date:8/22/2014)... 22, 2014 ... announced the addition of the  "Biometrics ... to their offering.       ... a technology that helps in the ... physical or behavioral features. It involves ...
(Date:8/22/2014)... Thomson Reuters , a leading source of information for ... University of California, Riverside in its 2014 list of ... times." , To generate the list, the company analyzed ... whose published work has had enormous impact. , The ... individuals who published the greatest number of highly cited ...
(Date:8/22/2014)... CA Research presented at the 29th Annual ... developed by Hera Therapeutics Inc. combats three types ... 70 percent of all cervical cancer. , When ... blocked the replication of HPV-16, HPV-18 and HPV-11 ... Thomas Broker, Ph.D., who presented the findings at ...
Breaking Biology News(10 mins):Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 2Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 35 UC Riverside scientists among world's most influential scientific minds 2
... is available in Polish . A ... mouse embryos can repair damaged brain circuitry and partially normalize ... obese due to a genetic deficiency. This proof-of-principle discovery represents ... which researchers hope might one day be used to repair ...
... National Taiwan University researchers have successfully manipulated the life span ... remove and restore protein functions related to yeast aging. ... in yeast acts like a life span clock: It is ... age. In a report in the September 16 edition ...
... and the University of Geneva have discovered a genetic mechanism ... genes play only a secondary role. The research published in ... mechanism is found in a DNA sequence that was thought, ... enhancers which, when combined with one another, modulate the activity ...
Cached Biology News:Metabolic defects in mice corrected with transplanted embryonic neurons 2Hopkins scientists turn on fountain of youth in yeast 2Finger (mal)formation reveals surprise function of desert DNA 2
Rabbit polyclonal to Flagellin ( Abpromise for all tested applications). Antigen: Synthetic peptide from the flagellin C terminal domain of Burkholderia pseudomallei....
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
... Killer Cell Receptor-P1, clone 1C10 ... Hybridoma produced by the ... mice immunized (BALB/c X C57BL/6)F1 ... and mouse myeloma cellline. ...
Phospho-SEK1/MKK4 (Thr261) Antibody...
Biology Products: